Vascular endothelial growth factor expression as a biomarker of prognosis in patients with chondrosarcoma, Ewings sarcoma and osteosarcoma. Current concepts

L. Capasso, M. Florio, M. Lillo, M. Basilico, V.De Santis, A. Ziranu, A. Grasso, F. Minutillo, G. Maccauro

Article ID: 6747
Vol 33, Issue 2S1, 2019
DOI: https://doi.org/10.54517/jbrha6747
Received: 9 May 2019; Accepted: 9 May 2019; Available online: 9 May 2019; Issue release: 9 May 2019

Abstract

With the advent of the molecularly targeted therapies, identifying molecular therapeutic targets and molecolar marker is increasingly important, especially in neoplastic diseases. Several studies show VEGF is involved in neo-angiogenesis in many solid cancers, as breast, lung, renal, gastric carcinomas, through promoting endothelial cell growth and migration. Conversely the relationship between VEFG and tumours of the musculoskeletal system is yet unclear, in particular the role of VEGF has not yet been completely understood in these tumours. Chondrosarcoma, Ewings Sarcoma and Osteosarcoma are the tumours of the musculoskeletal system in which the activity of VEGF has been closely studied. The present study aims to give an overview focused on the relationship between VEGF and these three cancers.


Keywords

osteosarcoma;chondrosarcoma;Ewing’s sarcoma;vascular endothelial growth factor;prognosis;biomarker;narrative review


References

Supporting Agencies



Copyright (c) 2019 L. Capasso, M. Florio, M. Lillo, M. Basilico, V.De Santis, A. Ziranu, A. Grasso, F. Minutillo, G. Maccauro




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).